Atossa Genetics Announces Issuance of Patent US9,052,318 by the U.S. Patent and Trademark for Breast Cancer Detection Using Absorbent Paper

SEATTLE, WA--(Jun 11, 2015) - Atossa Genetics Inc. (NASDAQ: ATOS), the Breast Health Company, announced today that the U.S. Patent and Trademark Office has issued a new patent, Serial No. 9,052,318, to Atossa, titled "Absorbent Paper and Uses Thereof for Breast Cancer Detection."

Dr. Steven Quay, Chairman, CEO & President of Atossa Genetics, said, "We are thrilled with the issuance of a U.S. patent for methods for identifying an individual's risk of developing breast cancer using absorbent paper to collect the individual's nipple aspirate fluid. Our patent estate now includes 147 issued patents and this particular patent is a big step forward in creating stockholder value and securing our proprietary rights to develop devices and tests that might one day be used to predict the risk of developing breast cancer based on the protein concentration and/or the number of cells, if any, in a breast fluid sample collected on an absorbent paper."

Atossa's medical devices and the laboratory tests offered by its wholly-owned subsidiary, The National Reference Laboratory for Breast Health Inc. (the "NRLBH") must receive regulatory clearance and/or approval from the U.S. Food and Drug Administration ("FDA") in order to market absorbent paper for medical use, including breast cancer risk assessment. These products and any related services related to them are not currently cleared or approved by the FDA for this or any other indication. The clinical safety and effectiveness of the use of absorbent paper for breast cancer detection with NAF has not been established and has not been reviewed by the FDA.

About Atossa Genetics

Atossa Genetics Inc. is focused on improving breast health through the development of laboratory services, medical devices and therapeutics. The laboratory services are being developed by the NRLBH. The laboratory services and the Company's medical devices are being developed so they can be used as companions to therapeutics to treat various breast health conditions. For more information, please visit www.atossagenetics.com.

Forward-Looking Statements

Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, the outcome or timing of regulatory approvals needed by Atossa to sell its products, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, recalls of products, the safety and efficacy of Atossa's products and services, performance of distributors, whether Atossa can launch in the United States and foreign markets the additional tests, devices and therapeutics in its pipeline in a timely and cost effective manner, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Atossa Genetics Inc.
Steven C. Quay, Ph.D., M.D.
Chairman, President and CEO
(O) 800-351-3902
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Relations:
CorProminence LLC
Scott Gordon
President
(O) 516-222-2560
This email address is being protected from spambots. You need JavaScript enabled to view it.